Arcutis Biotherapeutics, Inc. ARQT Investment Proceeds
Investment Proceeds at other companies
Other financials
Where this comes from
Reported directly by Arcutis Biotherapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities.
The official record: Arcutis Biotherapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Arcutis Biotherapeutics, Inc.'s investment proceeds.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Arcutis Biotherapeutics, Inc.'s investment proceeds?
- Arcutis Biotherapeutics, Inc. (ARQT) reported investment proceeds of $50.82M in Q1 2026.
- How has Arcutis Biotherapeutics, Inc.'s investment proceeds changed year-over-year?
- Arcutis Biotherapeutics, Inc.'s investment proceeds decreased by 25.8% year-over-year, from $68.47M to $50.82M.
- What is the long-term trend for Arcutis Biotherapeutics, Inc.'s investment proceeds?
- Over 4 years (2021 to 2025), Arcutis Biotherapeutics, Inc.'s investment proceeds has grown at a 1.1% compound annual growth rate (CAGR), from $217.55M to $227.42M.
- What does investment proceeds mean?
- Cash received from sales, maturities, and redemptions of investment securities across all categories.